Equillium, Inc. (EQ) Earnings Call Transcripts

Equillium, Inc.'s Latest Earnings Call - May 27, 2026

In the Q1 2026 earnings call for Equillium, Inc. (EQ:US), management discussed significant advancements in their research on the Aryl Hydrocarbon Receptor (AhR) and its relationship with miR-124, particularly in the context of ulcerative colitis treatment. The company highlighted that ABX464 is a moderately potent AhR modulator, with an EC50 of approximately 400 nanomolar, and confirmed that AhR modulation induces miR-124 expression, which is associated with anti-inflammatory effects. Revenue and earnings figures were not disclosed, and there were no changes to guidance, but management signaled ongoing progress towards clinical trials, particularly for EQ504, expected to initiate in Q3 2026.

Reported metrics

Guidance from management

Management maintained guidance for the initiation of the Phase I trial for EQ504 in Q3 2026, with no changes to financial guidance provided during the call.

What management said

Yes. No problem. Thanks, Tom. Well, look, the short of that is there's been no change. I'd refer you to the corporate deck there. The guidance still holds that we expect to initiate the study here in midyear, which we believe it brings up to Q3. So there'll be future updates pending on that as and when they're available, but I'll defer to the corporate deck for all of the deferred guidance.

Well, thank you for everybody who joined and perhaps stayed on 20 minutes past. We do very much appreciate everybody's time. Please do visit the website in the next few hours. The presentation will become live. There will be some additional data. Should you wish to engage in any of the conversations that have been had here, please do reach out via the appropriate channels to Equillium, and we'll be more than happy to...

What analysts pressed on

Analysts expressed concerns regarding the long-term efficacy and safety of ABX464, particularly in relation to its glucuronidated metabolites and their impact on AhR modulation in patients. Questions were raised about the durability of treatment effects in ulcerative colitis patients over time.

Main topics on the call

• AhR Modulation and miR-124 Relationship — Management confirmed that 'ABX464 is a moderately potent AhR modulator' and that 'AhR modulation induces miR-124,' which is linked to anti-inflammatory effects. This relationship is critical for understanding the therape...
• Clinical Trial Updates — Management indicated that the Phase I trial for EQ504 is expected to begin in Q3 2026, with a focus on achieving safe and effective dosing in ulcerative colitis patients. They emphasized the importance of engaging with t...
• Mechanistic Insights — The presentation provided insights into the mechanistic pathways of AhR and miR-124, suggesting that 'miR-124 seems to be induced by AhR in an AhR dependent fashion.' This understanding could enhance the therapeutic stra...
• Cytokine Modulation — Management highlighted the significance of IL-10 and IL-22 as key biomarkers for AhR modulation, stating that 'they seem to be centrally important to mucosal biology and health.' This focus aligns with the therapeutic go...

Read the full Equillium, Inc. transcript (May 27, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 9 Equillium, Inc. earnings call transcripts on record, spanning February 25, 2021 to May 27, 2026. Based on this history, Equillium, Inc. reports annually. The most recent call on file is dated May 27, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

EQ

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

9

First call

February 25, 2021

Most recent

May 27, 2026

Reporting cadence

annually